ESMO guidelines do not recommend local treatments with radical intent for EGFR-mutated and ALK-rearranged metastatic disease if it is not in the oligoprogressive scenario (see paragraph below), though the level of evidence is low due to the lack of randomised data. The gene discussed is ALK; the disease is metastatic neoplasm.